Molecular Targeting Unit is dedicated to study the role of cell cycle control in response to conventional and novel molecular targeted therapies and mechanisms of drug resistance.
Current Research projects in the In Hypoxia & Tumorigenesis Section:
Role of p53 in and checkpoint control in response to anticancer agentsLung Cancer: Discovery and validation of biomarkers for pulmonary neuroendocrine tumorsPreclinical models as tools for testing molecular targeted therapies Postdoctoral Opportunities
Staff Members
Lyuba Varticovski, MD
Adjunct Scientist
Staff Clinician, OD
Director, Preclinical Models Strategy Team
varticol@mail.nih.gov
Staff Scientist
roblesa@mail.nih.gov
Special Volunteer
feiss@mail.nih.gov
Pre-CRTA Fellow
salcidoc@mail.nih.gov
Pre-CRTA Fellow
carlsonm@mail.nih.gov